IMPORTANT SAFETY INFORMATION
Warnings and Precautions
In a pool of 12 placebo-controlled studies, the most common adverse reactions (≥5%) associated with FARXIGA 5 mg, 10 mg, and placebo respectively were female genital mycotic infections (8.4% vs 6.9% vs 1.5%), nasopharyngitis (6.6% vs 6.3% vs 6.2%), and urinary tract infections (5.7% vs 4.3% vs 3.7%).
Use in Specific Populations
INDICATIONS AND LIMITATIONS OF USE FOR FARXIGA
FARXIGA is indicated:
FARXIGA is not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
Please read US Full Prescribing Information and Medication Guide for FARXIGA.
You may report side effects related to AstraZeneca products by clicking here.
CV=cardiovascular; eCVD=established cardiovascular disease; FDA=US Food and Drug Administration; HFrEF=heart failure with reduced ejection fraction; hHF=hospitalization for heart failure; SGLT2i=sodium-glucose cotransporter 2 inhibitor; T2D=type 2 diabetes.
References: 1. FARXIGA® (dapagliflozin) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020. 2. Invokana® (canagliflozin) [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2020. 3. Jardiance® (empagliflozin) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2020. 4. Steglatro™ (ertugliflozin) [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2020.
FARXIGA is a registered trademark of the AstraZeneca group of companies.
©2020 AstraZeneca. All rights reserved.
US-42882 Last Updated 8/20